LICENSE AGREEMENTLicense Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 3rd, 2011 Company Industry JurisdictionThis LICENSE AGREEMENT (“Agreement”) is made and entered into as of January 4, 2006, (“Effective Date”) by and between CyDex, Inc. (“CyDex” or “Licensor”), a corporation with its principal place of business located at 10513 W. 84th Terrace, Lenexa, Kansas 66214, and PRISM PHARMACEUTICALS, INC. (“Prism” or “Licensee”), a Delaware corporation, with its principal place of business located at 1150 First Ave, Suite 1050, King of Prussia, Pennsylvania, 19406, each a “Party” and together the “Parties.”
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 3rd, 2011 Company Industry JurisdictionThis AMENDMENT to the certain License Agreement dated January 4, 2006 between CYDEX, INC. (“CyDex” or “Licensor”), a corporation with its principal place of business located at 10513 W. 84th Terrace, Lenexa, Kansas 66214, and PRISM PHARMACEUTICALS, INC. (“Prism” or “Licensee”), a Delaware corporation, with its principal place of business located at 1150 First Ave., Suite 1050, King of Prussia, Pennsylvania, 19406, granting an exclusive license under the Product Intellectual Property for the development, use and sale of Licensed Products in the Field of Use and throughout the Territory (the “License Agreement”), is made and entered into as of May 12, 2006 (the “Effective Date”) by and between CyDex and Prism.
CAPTISOL® SUPPLY AGREEMENTCaptisol Supply Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 3rd, 2011 Company Industry JurisdictionCYDEX desires to purchase from HOVIONE, and HOVIONE desires to supply to CYDEX, CAPTISOL in accordance with the terms and conditions of this AGREEMENT.
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE AGREEMENTLicense Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Kansas
Contract Type FiledMarch 3rd, 2011 Company Industry JurisdictionTHIS LICENSE AGREEMENT is made and entered into this 3rd day of September, 1993 by and between THE UNIVERSITY OF KANSAS (“KU”), a not for profit Kansas corporation having offices at 226 Strong Hall, Lawrence, Kansas 66045, and CyDex L.C. (“CyDex”), a Kansas limited liability company having an office at 8675 W. 96th Street, Suite 207, Overland Park, Kansas 66212.
2nd Amendment to the CAPTISOL® SUPPLY AGREEMENT dated as of December 20, 2002 and amended July 29, 2005 BY AND BETWEEN CYDEX, INC. AND THE HOVIONE GROUP Dated as of March 1, 2007Captisol® Supply Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 3rd, 2011 Company Industry Jurisdiction
1st Amendment to the CAPTISOL® SUPPLY AGREEMENTCaptisol® Supply Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
Contract Type FiledMarch 3rd, 2011 Company Industry
CAPTISOL® SUPPLY AGREEMENTCaptisol® Supply Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 3rd, 2011 Company Industry Jurisdiction
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. NONEXCLUSIVE LICENSE AGREEMENTNonexclusive License Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Kansas
Contract Type FiledMarch 3rd, 2011 Company Industry JurisdictionThis License Agreement is entered into as of the 4th day of June, 1996 (the “Effective Date”) by and between Pfizer Inc., a Delaware corporation having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and the University of Kansas, a state educational institution of the State of Kansas with a place of business at Office of Research Support and Grants Administration, Strong Hall, Lawrence, Kansas 66045 and its Affiliates (“KU”) (each individually a “Party” and collectively the “Parties”).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. SECOND AMENDMENT TO LICENSE...License Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
Contract Type FiledMarch 3rd, 2011 Company IndustryTHIS SECOND AMENDMENT TO LICENSE AGREEMENT (the “Amendment”) is made and entered into this 4th day of August, 2004 (the “Amendment Date”) by and between THE UNIVERSITY OF KANSAS (“KU”), having offices at Youngberg Hall, 2385 Irving Hill Road, Lawrence, Kansas 66044, and CyDex, Inc. (“CyDex”), a Delaware corporation having an office at 12980 Metcalf Avenue, Suite 470, Overland Park, Kansas 66213.
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Kansas
Contract Type FiledMarch 3rd, 2011 Company Industry JurisdictionThis License Agreement is entered into as of the 4th day of June, 1996 (the “Effective Date”) by and between Pfizer Inc., a Delaware corporation. having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”) and the University of Kansas, a state educational institution of the State of Kansas with a place of business at Office of Research Support and Grants Administration, Strong Hall, Lawrence, Kansas 66045 and its Affiliates (“KU”) (each individually a “Party” and collectively the “Parties”).
SUPPLY AGREEMENTSupply Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 3rd, 2011 Company Industry JurisdictionTHIS SUPPLY AGREEMENT (this “Agreement”) is made this 5th day of March, 2007 (the “Effective Date”), by and between CyDex, Inc., a Delaware corporation with offices at 10513 W. 84th Terrace, Lenexa, Kansas 66214 (“CyDex”), and Prism Pharmaceuticals, Inc., a Delaware corporation with offices at 1150 First Ave, Suite 1050, King of Prussia, Pennsylvania 19406 (“Prism”).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Captisol Supply Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 3rd, 2011 Company Industry Jurisdiction
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.License Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
Contract Type FiledMarch 3rd, 2011 Company Industry